Eagle Wealth Strategies LLC Lowers Stake in Vertex Pharmaceuticals Incorporated $VRTX

Eagle Wealth Strategies LLC reduced its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 13.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 473 shares of the pharmaceutical company’s stock after selling 71 shares during the period. Eagle Wealth Strategies LLC’s holdings in Vertex Pharmaceuticals were worth $211,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Advisor OS LLC raised its holdings in Vertex Pharmaceuticals by 4.4% in the first quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock worth $263,000 after buying an additional 23 shares during the last quarter. Avidian Wealth Enterprises LLC raised its holdings in Vertex Pharmaceuticals by 2.1% in the first quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company’s stock worth $594,000 after buying an additional 25 shares during the last quarter. Strategic Blueprint LLC raised its holdings in Vertex Pharmaceuticals by 1.7% in the first quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company’s stock worth $726,000 after buying an additional 25 shares during the last quarter. Breakwater Capital Group raised its holdings in Vertex Pharmaceuticals by 1.5% in the first quarter. Breakwater Capital Group now owns 1,786 shares of the pharmaceutical company’s stock worth $866,000 after buying an additional 27 shares during the last quarter. Finally, Hager Investment Management Services LLC raised its holdings in Vertex Pharmaceuticals by 0.5% in the first quarter. Hager Investment Management Services LLC now owns 5,411 shares of the pharmaceutical company’s stock worth $2,623,000 after buying an additional 27 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Royal Bank Of Canada decreased their target price on shares of Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating for the company in a report on Tuesday, August 5th. Morgan Stanley set a $439.00 price objective on shares of Vertex Pharmaceuticals and gave the company an “equal weight” rating in a report on Tuesday, August 5th. BMO Capital Markets set a $530.00 price objective on shares of Vertex Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, August 5th. Stifel Nicolaus decreased their price objective on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a report on Tuesday, August 5th. Finally, Wall Street Zen cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, August 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $493.81.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs purchased 5,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the transaction, the director directly owned 45,000 shares in the company, valued at $17,535,600. This trade represents a 12.50% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Trading Up 2.5%

Shares of NASDAQ VRTX opened at $395.31 on Tuesday. The firm has a 50 day moving average of $404.74 and a 200 day moving average of $445.10. The firm has a market capitalization of $101.35 billion, a price-to-earnings ratio of 28.26 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.28. The company had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.